Meta-Analysis Is Not Appropriate for Burden of Disease Estimates

Published Jul 3, 2014
Brisbane, Australia - In burden of disease studies, decisions about the pooling of estimates, such as prevalence across countries, are largely made using conventional meta-analysis models. However, when there is true diversity and dissimilarity of effects, meta-analysis is not recommended. If the ultimate aim is to generate an average estimate of the disease measure across populations, there is a need to conduct sub-population-standardization, to account for differences in sub-population distribution within the populations from which primary disease measures are drawn. In the article “An Updated Method for Risk Adjustment in Outcomes Research,” published in Value in Health, researchers from theUniversity of Queensland in Brisbane describe how meta-analytic methods can be adapted to synthesize descriptive epidemiological data from different populations to arrive at pooled estimates for specific disease measures. In addition, internal and external standardization are distinguished for the first time. This approach enables a more accurate estimation of the standardized effect, and also simplifies the process of estimation of pooled measures to assess global or regional burden of disease. “Using meta-analytic methods in standardization makes it easier to carry out such pooled analyses of measures of incidence and prevalence, and this will lead to a more realistic reporting of the magnitude of global burden from different conditions, as well as differentials in disease burden across populations” said Suhail Doi, PhD who is from the University of Queensland. Having more realistic results will enhance decision making for intervention programs, for example, more equitable allocation of resources for such interventions.

Value in Health (ISSN 1098-3015) publishes papers, concepts, and ideas that advance the field of pharmacoeconomics and outcomes research as well as policy papers to help health care leaders make evidence-based decisions. The journal is published bi-monthly and has over 8,000 subscribers (clinicians, decision-makers, and researchers worldwide).

International Society for Pharmacoeconomics and Outcomes Research (ISPOR) is a nonprofit, international, educational and scientific organization that strives to increase the efficiency, effectiveness, and fairness of health care resource use to improve health.

For more information: www.ispor.org

Related Stories

International Study Confirms Universally Applicable Framework for Defining Digital Health Interventions

Jan 21, 2026

Value in Health, the official journal of ISPOR—The Professional Society for Health Economics and Outcomes Research, announced today the publication of a comprehensive international study demonstrating that the PICOTS-ComTeC framework serves as an effective universal standard for defining patient-facing digital health interventions. The report, “Towards a Common Ground for Defining Digital Health Interventions, Mapping Digital Health Frameworks to PICOTS-ComTeC: An ISPOR Special Interest Group Report” was published in the January 2026 issue of Value in Health.

New Research Collection Reveals How Artificial Intelligence Is Reshaping Health Economics

Nov 6, 2025

The PhRMA Foundation and ISPOR announced the publication of a special themed section of research papers that explores the dynamic intersection of artificial intelligence (AI) and health economics and outcomes research (HEOR).

ISPOR Announces 2025 Health Economics and Outcomes Research Award Honorees

Oct 20, 2025

ISPOR announced the recipients of its 2025 Health Economics and Outcomes Research (HEOR) Scientific and Leadership Awards. ISPOR Scientific Awards are designed to foster and recognize excellence and outstanding achievement in HEOR and its Leadership Awards recognize excellence and outstanding leadership in the field.
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×